{"paper_id":"f2cd3d77-b685-4017-b462-9726d11ad451","body_text":"Abstract\nThe aim of the present study was to evaluate the clinical usefulness of the cytokeratin marker CYFRA 21-1 as a screening marker for ovarian cancer, as a predictive marker in patients with adnexal masses and as a prognostic marker in women suffering from ovarian cancer. In order to determine the specificity of the CYFRA 21-1 test, we have investigated CYFRA 21-1 serum levels in several benign conditions. This retrospective study comprises 37 patients suffering from ovarian cancer FIGO stages Ia-III. Sera from patients with benign ovarian cysts, endometriosis, pelvic inflammatory disease, inflammatory bowel disease and liver cirrhosis were evaluated in 90, 10, 38, 10 and 20 cases respectively. With a sensitivity of 41% and a specificity of 95%, CYFRA 21-1 was not suitable as a screening marker for ovarian cancer. Although CYFRA 21-1 was able to discriminate between ovarian cancer and benign adnexal tumours (univariate regression model, P = 0.0001), CYFRA 21-1 did not reveal additional information to CA 125 in a multivariate regression analysis (P = 0.06). CYFRA 21-1 serum levels were elevated in benign conditions such as liver cirrhosis, but not in endometriosis and inflammatory diseases. In ovarian cancer patients, elevated CYFRA 21-1 serum levels before therapy were associated with a poor overall and disease-free survival (log-rank test, P = 0.02 and log-rank test, P = 0.005 respectively). CYFRA 21-1, while obviously not suitable for screening or differential diagnosis of adnexal masses, could be useful as an additional prognostic factor in ovarian cancer patients.\nThis is a preview of subscription content, access via your institution\nAccess options\nSubscribe to this journal\nReceive 24 print issues and online access\n251,40 € per year\nonly 10,48 € per issue\nBuy this article\n- Purchase on SpringerLink\n- Instant access to the full article PDF.\n39,95 €\nPrices may be subject to local taxes which are calculated during checkout\nSimilar content being viewed by others\nAuthor information\nAuthors and Affiliations\nRights and permissions\nAbout this article\nCite this article\nTempfer, C., Hefler, L., Heinzl, H. et al. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases. Br J Cancer 78, 1108–1112 (1998). https://doi.org/10.1038/bjc.1998.636\nIssue date:\nDOI: https://doi.org/10.1038/bjc.1998.636\nThis article is cited by\n-\nA high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer\nCancer Chemotherapy and Pharmacology (2013)","source_license":"public-domain-us","license_restricted":false}